PRODUCT
FDA Delays Decision on Biohaven’s Troriluzole for Rare Disease, Plans Advisory Committee Review
Biohaven; FDA delay; troriluzole; spinocerebellar ataxia (SCA); rare disease drug; PDUFA extension; advisory committee; neurodegenerative disease
Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus
Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101
OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios
OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset
FDA eyes full AI integration by June as Makary touts genAI pilot success
United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Regeneron crumples under the weight of missed Eylea expectations
Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity
Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal
Creyon, Eli Lilly, Eli, Oligonucleotides
CMS would absorb 340B drug discount program under leaked HHS reorganization proposal
340B, Centers for Medicare and Medicaid Services, HHS, reorganization, Programs – Publication Format, proposal – intent, drug discount program, United States Health Resources and Services Administration, CMS, Policy, Leaked, Changing
German cancer antibody biotech eyes SPAC as route to Nasdaq
Veraxa, Antibodies, SPAC, German language, Nasdaq
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy